Investors considering a purchase of Harrow Inc (Symbol: HROW) stock, but tentative about paying the going market price of $35.48/share, might benefit from considering selling puts among the ...
Harrow's focused acquisition model in ophthalmic drugs enables high growth, with a diversified portfolio and limited R&D expenses. My DCF analysis suggests a fair value of $72.75 per share—nearly 100% ...
Harrow, Inc. is a strong swing trade in the $20s, with long-term upside as sales and new product launches drive sustained profits. Recent licensing of BYQLOVI and the VEVYE Access for All program are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback